

# With Trust, Fearful Parents Will OK Child Shots

BY MIRIAM E. TUCKER  
Senior Writer

WASHINGTON — Even parents who don't trust vaccines might let you vaccinate their children if they trust you.

That was the conclusion drawn from a survey of parents of 7,810 children aged 19-35 months from the 2001-2002 National Immunization Survey, conducted by Philip J. Smith, Ph.D., and his associates at the Centers for Disease Control

and Prevention's National Immunization Program, in Atlanta.

The majority of parents (77%) said they believed vaccines were safe and that their belief was influenced by their child's healthcare provider (physician, nurse, or other). However, 5.7% of parents reported believing that vaccines were not safe, with 2% saying they were not influenced by their child's healthcare provider and the 3.7% reporting that they were.

Another 17.2% said that they believed

vaccines were safe but their belief was not influenced by a healthcare provider. This group is of concern, because "One thing we don't want to happen is that these parents' opinions migrate to the other side," Dr. Smith said at the annual meeting of the American Academy of Pediatrics.

Parents who were not influenced by a healthcare provider were significantly more likely to say that vaccines

were not safe, compared with parents who were so influenced (10.4% vs. 4.6%).

Somewhat surprising, however, were the up-to-date immunization rates among the children of the parents who believe that immunizations are not safe: 71.5% for those who said they were influenced by a healthcare provider, compared with just

55.8% of those who were not, a highly significant difference. "All this is pointing to the importance of a healthcare provider talking with the parent," Dr. Smith said.

Indeed, earlier this year the American Academy of Pediatrics published guidelines on how to respond to parental refusal of immunization for their children (Pediatrics 2005;115:1428-31). Among AAP's recommendations are to listen respectfully to what the parents have to say and not minimize their concerns. Be honest about the benefits and risks of immunization, correct any misconceptions or misinformation, and refer the parents to trusted sources such as the CDC's National Immunization Program page ([www.cdc.gov/nip](http://www.cdc.gov/nip)).

## S. aureus Is Agent of Fatal Syndrome

Three children diagnosed with Waterhouse-Friderichsen syndrome died after rapidly progressive illness was traced to severe *Staphylococcus aureus* infection, said Patricia V. Adom, M.D., of the University of Chicago, and her associates.

The three patients—a 15-month-old girl, a 9-month-old girl, and a 17-month-old boy—had been in good health prior to the onset of infection. Premortem cultures yielded methicillin-susceptible *S. aureus* in the first patient and methicillin-resistant *S. aureus* (MRSA) in the next two patients. All the isolates were genetically related, which underscores the rise in community-associated MRSA, the investigators said (N. Engl. J. Med. 2005;353:1245-51).

Characteristics of Waterhouse-Friderichsen syndrome include petechial rash, coagulopathy, cardiovascular collapse, and bilateral adrenal hemorrhage. Although extracorporeal membrane oxygenation has been associated with adrenal hemorrhage in other studies, it was not associated with fatal illness in the two patients in this review who received it.

Noteworthy clinical features in all three children included leukopenia, neutropenia, profound tachycardia, and profound metabolic acidosis, and the course of the disease resembled fulminant meningococemia.

Pathologic findings revealed severe sepsis and disseminated intravascular coagulation, but there was no evidence of myocarditis or endocarditis. The lungs of all three patients showed gram-positive cocci in clusters, some of which were found in the vascular walls.

—Heidi Splette

Brief Summary of Prescribing Information (Nos. 1541, 1543, 1544, 3046, 7309, 7311) 03-5366-R24-Brf. Rev. July, 2004

**PREVACID®** (lansoprazole) Delayed-Release Capsules

**PREVACID®** (lansoprazole) For Delayed-Release Oral Suspension

**PREVACID® SoluTab™** (lansoprazole) Delayed-Release Orally Disintegrating Tablets

**Rx only**

**PREVACID Delayed-Release Capsules, PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets and PREVACID For Delayed-Release Oral Suspension are indicated for:**

**Short-Term Treatment (4 weeks) of Active Duodenal Ulcer**

**H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence**

**Maintenance of Healed Duodenal Ulcers**

**Short-Term Treatment (up to 8 weeks) of Active Benign Gastric Ulcer**

**Healing of NSAID-Associated Gastric Ulcer**

**Risk Reduction of NSAID-Associated Gastric Ulcer**

**Gastroesophageal Reflux Disease (GERD)**

**Short-Term Treatment of Symptomatic GERD**

**Short-Term Treatment (up to 8 weeks) of Erosive Esophagitis**

**Maintenance of Healing of Erosive Esophagitis**

**Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome**

**CONTRAINDICATIONS**

PREVACID is contraindicated in patients with known hypersensitivity to any component of the formulation of PREVACID.

Amoxicillin is contraindicated in patients with a known hypersensitivity to any penicillin.

Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, and any of the macrolide antibiotics.

Concomitant administration of clarithromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated. There have been post-marketing reports of drug interactions when clarithromycin and/or erythromycin are co-administered with cisapride, pimozide, astemizole, or terfenadine resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by erythromycin and clarithromycin. Fatalities have been reported.

(Please refer to full prescribing information for amoxicillin and clarithromycin before prescribing.)

**WARNINGS**

CLARITHROMYCIN SHOULD NOT BE USED IN PREGNANT WOMEN EXCEPT IN CLINICAL CIRCUMSTANCES WHERE NO ALTERNATIVE THERAPY IS APPROPRIATE. IF PREGNANCY OCCURS WHILE TAKING CLARITHROMYCIN, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD TO THE FETUS. (SEE WARNINGS IN PRESCRIBING INFORMATION FOR CLARITHROMYCIN.)

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including clarithromycin and amoxicillin, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by *Clostridium difficile* is a primary cause of "antibiotic-associated colitis."

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to discontinuation of the drug alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, proton supplementation, and treatment with an antibacterial drug clinically effective against *Clostridium difficile* colitis.

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy. These reactions are more apt to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens.

There have been well-documented reports of individuals with a history of penicillin hypersensitivity reactions who have experienced severe hypersensitivity reactions when treated with a cephalosporin. Before initiating therapy with any penicillin, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, and other allergens. If an allergic reaction occurs, amoxicillin should be discontinued and the appropriate therapy instituted.

SEVERE ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE, OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.

**PRECAUTIONS**

**General**

Symptomatic response to therapy with lansoprazole does not preclude the presence of gastric malignancy.

**Information for Patients**

PREVACID is available as a capsule, orally disintegrating tablet and oral suspension, and is available in 15 mg and 30 mg strengths. Directions for use specific to the route and available methods of administration for each of these dosage forms is presented below. PREVACID should be taken before eating. PREVACID products SHOULD NOT BE CRUSHED OR CHEWED.

**Phenylketonurics: Contains Phenylalanine 2.5 mg per 15 mg Tablet and 5.1 mg per 30 mg Tablet.**

**Administration Options**

1. **PREVACID Delayed-Release Capsules**

PREVACID Delayed-Release Capsules should be swallowed whole.

Alternatively, for patients who have difficulty swallowing capsules, PREVACID Delayed-Release Capsules can be opened and administered as follows:

• Open capsule.

• Sprinkle intact granules on one tablespoon of either applesauce, ENSURE® pudding, cottage cheese, yogurt or strained pears.

• Swallow immediately.

PREVACID Delayed-Release Capsules may also be emptied into a small volume of either apple juice, orange juice or tomato juice and administered as follows:

• Open capsule.

• Sprinkle intact granules into a small volume of either apple juice, orange juice or tomato juice (60 mL – approximately 2 ounces).

• Mix briefly.

• Swallow immediately.

• To ensure complete delivery of the dose, the glass should be rinsed with two or more volumes of juice and the contents swallowed immediately.

USE IN OTHER FOODS AND LIQUIDS HAS NOT BEEN STUDIED CLINICALLY AND IS THEREFORE NOT RECOMMENDED.

2. **PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets**

PREVACID SoluTab should not be chewed. Place the tablet on the tongue and allow it to disintegrate, with or without water, until the particles can be swallowed. The tablet typically disintegrates in less than 1 minute.

Alternatively, for children or other patients who have difficulty swallowing tablets, PREVACID SoluTab can be delivered in two different ways.

**PREVACID SoluTab – Oral Syringe**

For administration via oral syringe, PREVACID SoluTab can be administered as follows:

• Place a 15 mg tablet in oral syringe and draw up approximately 4 mL of water, or place a 30 mg tablet in oral syringe and draw up approximately 10 mL of water.

• Shake gently to allow for a quick dispersal.

• After the tablet has dispersed, administer the contents within 15 minutes.

• Refill the syringe with approximately 2 mL (5 mL for the 30 mg tablet) of water, shake gently, and administer any remaining contents.

**PREVACID SoluTab – Nasogastric Tube Administration (≥ 8 French)**

For administration via a nasogastric tube, PREVACID SoluTab can be administered as follows:

• Place a 15 mg tablet in a syringe and draw up 4 mL of water, or place a 30 mg tablet in a syringe and draw up 10 mL of water.

• Shake gently to allow for a quick dispersal.

• After the tablet has dispersed, inject through the nasogastric tube into the stomach within 15 minutes.

• Refill the syringe with approximately 5 mL of water, shake gently, and flush the nasogastric tube.

3. **PREVACID For Delayed-Release Oral Suspension**

PREVACID For Delayed-Release Oral Suspension should be administered as follows:

• Open packet.

• To prepare a dose, empty the packet contents into a container containing 2 tablespoons of WATER. DO NOT USE OTHER LIQUIDS OR FOODS.

• Stir well, and drink immediately.

• If any material remains after drinking, add more water, stir, and drink immediately.

• This product should not be given through enteral administration tubes.

**Drug Interactions**

Lansoprazole is metabolized through the cytochrome P<sub>450</sub> system, specifically through the CYP3A and CYP2C19 isozymes. Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P<sub>450</sub> system, such as warfarin, antizyme, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects. These compounds are metabolized through various cytochrome P<sub>450</sub> isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A. When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen. Because of the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be of clinical concern. Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.

In a study of healthy subjects neither the pharmacokinetics of warfarin enantiomers nor prothrombin time were affected following single or multiple 60 mg doses of lansoprazole. However, there have been reports of increased International Normalized Ratio (INR) and prothrombin time in patients receiving proton pump inhibitors, including lansoprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.

Lansoprazole has also been shown to have no clinically significant interaction with amoxicillin.

In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate. Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate. In clinical trials, antacids were administered concomitantly with PREVACID Delayed-Release Capsules; this did not interfere with its effect.

Lansoprazole causes a profound and long-lasting inhibition of gastric acid secretion; therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin).

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

In two 24-month carcinogenicity studies, Sprague-Dawley rats were treated orally with doses of 5 to 150 mg/kg/day, about 1 to 40 times the exposure on a body surface (mg/m<sup>2</sup>) basis, of a 50-kg person of average height (1.46 m<sup>2</sup> body surface area) given the recommended human dose of 30 mg/day (22.2 mg/m<sup>2</sup>). Lansoprazole produced dose-related gastric enterochromaffin-like (ECL) cell hyperplasia and ECL cell carcinoids in both male and female rats. It also increased the incidence of intestinal metaplasia of the gastric epithelium in both sexes. In male rats, lansoprazole produced a dose-related increase of testicular interstitial cell adenomas. The incidence of these adenomas in rats receiving doses of 15 to 150 mg/kg/day (4 to 40 times the recommended human dose based on body surface area) exceeded the low background incidence (range = 1.4 to 10%) for this strain of rat. Testicular interstitial cell adenoma also occurred in 1 of 30 rats treated with 50 mg/kg/day (13 times the recommended human dose based on body surface area) in a 1-year toxicity study.

In a 24-month carcinogenicity study, CD-1 mice were treated orally with doses of 15 to 600 mg/kg/day, 2 to 80 times the recommended human dose based on body surface area. Lansoprazole produced a dose-related increase of incidence of gastric ECL cell hyperplasia. It also produced an increased incidence of liver tumors (hepatocellular adenoma plus carcinoma). The tumor incidences in male mice treated with 300 and 600 mg/kg/day (40 to 80 times the recommended human dose based on body surface area) and female mice treated with 150 to 600 mg/kg/day (20 to 80 times the recommended human dose based on body surface area) exceeded the ranges of background incidences in historical controls for this strain of mice. Lansoprazole treatment produced adenomas of rete testis in male mice receiving 75 to 600 mg/kg/day (10 to 80 times the recommended human dose based on body surface area).

Lansoprazole was not genotoxic in the Ames test, the *ex vivo* rat hepatocyte unscheduled DNA synthesis (UDS) test, the *in vivo* mouse micronucleus test or the rat bone marrow cell chromosomal aberration test. It was positive in *in vitro* human lymphocyte chromosomal aberration assays.

Lansoprazole at oral doses up to 150 mg/kg/day (40 times the recommended human dose based on body surface area) was found to have no effect on fertility and reproductive performance of male and female rats.

**Pregnancy: Teratogenic Effects.**

**Pregnancy Category B**

**Lansoprazole**

Teratology studies have been performed in pregnant rats at oral doses up to 150 mg/kg/day (40 times the recommended human dose based on body surface area) and pregnant rabbits at oral doses up to 30 mg/kg/day (16 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to lansoprazole.

There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

**Pregnancy Category C**

**Clarithromycin**

See WARNINGS (above) and full prescribing information for clarithromycin before using in pregnant women.

**Nursing Mothers**

Lansoprazole or its metabolites are excreted in the milk of rats. It is not known whether lansoprazole is excreted in human milk. Because many drugs are excreted in human milk, because of the potential for serious adverse reactions in nursing infants from lansoprazole, and because of the potential for tumorigenicity shown for lansoprazole in rat carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

**Pediatric Use**

The safety and effectiveness of PREVACID have been established in pediatric patients 1 to 17 years of age for short-term treatment of symptomatic GERD and erosive esophagitis. Use of PREVACID in this population is supported by evidence from adequate and well-controlled studies of PREVACID in adults with additional clinical, pharmacokinetic, and pharmacodynamic studies performed in pediatric patients. The adverse events profile in pediatric patients is similar to that of adults. There were no adverse events reported in U.S. clinical studies that were not previously observed in adults. The safety and effectiveness of PREVACID in patients <1 year of age have not been established.

**1 to 11 years of age**

The pediatric safety of PREVACID Delayed-Release Capsules has been assessed in 66 pediatric patients aged 1 to 11 years of age. Of the 66 patients with GERD 85% (56/66) took PREVACID for 8 weeks and 15% (10/66) took it for 12 weeks.

The most frequently reported (2 or more patients) treatment-related adverse events in patients 1 to 11 years of age (N=66) were constipation (5%) and headache (3%).

**12 to 17 years of age**

The safety of PREVACID Delayed-Release Capsules has been assessed in these 87 adolescent patients. Of the 87 adolescent patients with GERD, 6% (5/87) took PREVACID for <6 weeks, 93% (81/87) for 6-10 weeks, and 1% (1/87) for >10 weeks.

The most frequently reported (at least 3%) treatment-related adverse events in these patients were headache (7%), abdominal pain (5%), nausea (3%) and dizziness (3%). Treatment-related dizziness, reported in this package insert as occurring in <1% of adult patients, was reported in this study by 3 adolescent patients with nonerosive GERD, who had dizziness concurrently with other events (such as migraine, dyspnea, and vomiting).

**Use in Women**

Over 4,000 women were treated with lansoprazole. Ulcer healing rates in females were similar to those in males. The incidence rates of adverse events were also similar to those seen in males.

**Use in Geriatric Patients**

Ulcer healing rates in elderly patients are similar to those in a younger age group. The

incidence rates of adverse events and laboratory test abnormalities are also similar to those seen in younger patients. For elderly patients, dosage and administration of lansoprazole need not be altered for a particular indication.

**ADVERSE REACTIONS**

**Clinical**

Worldwide, over 10,000 patients have been treated with lansoprazole in Phase 2-3 clinical trials involving various dosages and durations of treatment. The adverse reaction profiles for PREVACID Delayed-Release Capsules and PREVACID For Delayed-Release Oral Suspension are similar. In general, lansoprazole treatment has been well-tolerated in both short-term and long-term trials.

The following adverse events were reported by the treating physician to have a possible or probable relationship to drug in 1% or more of PREVACID-treated patients and occurred at a greater rate in PREVACID-treated patients than placebo-treated patients:

**Incidence of Possibly or Probably Treatment-Related Adverse Events in Short-Term, Placebo-Controlled Studies**

Body System/Adverse Event	PREVACID (N= 2768)	Placebo (N= 1023)
	%	%
Body as a Whole		
Abdominal Pain	2.1	1.2
Digestive System		
Constipation	1.0	0.4
Diarrhea	3.8	2.3
Nausea	1.3	1.2

Headache was also seen at greater than 1% incidence but was more common on placebo. The incidence of diarrhea was similar between patients who received placebo and patients who received lansoprazole 15 mg and 30 mg, but higher in the patients who received lansoprazole 60 mg (2.9%, 1.4%, 4.2%, and 7.4%, respectively).

The most commonly reported possibly or probably treatment-related adverse event during maintenance therapy was diarrhea.

In the risk reduction study of PREVACID for NSAID-associated gastric ulcers, the incidence of diarrhea for patients treated with PREVACID was 5%, misoprostol 22%, and placebo 3%.

Additional adverse experiences occurring in <1% of patients or subjects in domestic trials are shown below. Refer to **Postmarketing** for adverse reactions occurring since the drug was marketed.

**Body as a Whole** – abdomen enlarged, allergic reaction, asthenia, back pain, candidiasis, carcinoma, chest pain (not otherwise specified), chills, edema, fever, flu syndrome, hantavirus, infection (not otherwise specified), malaise, neck pain, neck rigidity, pain, pelvic pain; **Cardiovascular System** – angina, arrhythmia, bradycardia, cerebrovascular accident/cerebral infarction, hypertension/hypotension, migraine, myocardial infarction, palpitations, shock (circulatory failure), syncope, tachycardia, vasodilation; **Digestive System** – abnormal stools, anorexia, eructation, esophageal stenosis, esophageal ulcer, esophagitis, fecal discoloration, flatulence, gastric nodules/fundic gland polyps, gastritis, gastroenteritis, gastrointestinal anomaly, gastrointestinal disorder, gastrointestinal hemorrhage, glossitis, gum hemorrhage, hematemesis, increased appetite, increased salivation, melena, mouth ulceration, nausea and vomiting, nausea and vomiting and diarrhea, oral moniliasis, rectal disorder, rectal hemorrhage, stomatitis, tenesmus, thirst, tongue disorder, ulcerative colitis, ulcerative stomatitis; **Endocrine System** – diabetes mellitus, goiter, hypothyroidism; **Hemic and Lymphatic System** – anemia, hemolysis, lymphadenopathy; **Metabolic and Nutritional Disorders** – gout, dehydration, hyperglycemia/hypoglycemia, peripheral edema, weight gain/loss; **Musculoskeletal System** – arthralgia, arthritis, bone disorder, joint disorder, leg cramps, musculoskeletal pain, myalgia, myasthenia, myositis; **Nervous System** – abnormal dreams, agitation, amnesia, anxiety, apathy, confusion, convulsion, depersonalization, depression, diplopia, dizziness, emotional lability, hallucinations, hemiplegia, hostility aggravated, hyperkinesia, hypertension, hypesthesia, insomnia, libido decreased/increased, neuroticism, neuritis, paresthesia, sleep disorder, somnolence, thinking abnormality, tremor, vertigo; **Respiratory System** – asthma, bronchitis, cough increased, dyspnea, epistaxis, hemoptysis, hiccup, laryngeal neoplasia, pharyngitis, pleural disorder, pneumonia, respiratory disorder, upper respiratory inflammation/infection, rhinitis, sinusitis, stridor; **Skin and Appendages** – acne, alopecia, contact dermatitis, dry skin, fixed eruption, hair disorder, maculopapular rash, nail disorder, pruritus, rash, skin carcinoma, skin disorder, sweating, urticaria; **Special Senses** – abnormal vision, blurred vision, conjunctivitis, deafness, dry eyes, ear disorder, eye pain, otitis media, parosmia, photophobia, retinal degeneration, taste loss, taste perversion, tinnitus, visual field defect; **Urogenital System** – abnormal menses, breast enlargement, breast pain, breast tenderness, dysmenorrhea, dysuria, gynecostasia, impotence, kidney calculus, kidney pain, leukorrhea, menorrhagia, menstrual disorder, penis disorder, polyuria, testis disorder, urethral pain, urinary frequency, urinary tract infection, urinary urgency, urination impaired, vaginitis.

**Postmarketing**

On-going Safety Surveillance: Additional adverse experiences have been reported since lansoprazole has been marketed. The majority of these cases are foreign-sourced and a relationship to lansoprazole has not been established. Because these events were reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events are listed below by COSTART® body system.

**Body as a Whole** – anaphylactoid-like reaction; **Digestive System** – hepatotoxicity, pancreatitis, vomiting; **Hemic and Lymphatic System** – agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, neutropenia, pancytopenia, thrombocytopenia, and thrombotic thrombocytopenic purpura; **Skin and Appendages** – severe dermatologic reactions including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (some fatal); **Special Senses** – speech disorder; **Urogenital System** – urinary retention.

**Combination Therapy with Amoxicillin and Clarithromycin**

In clinical trials using combination therapy with PREVACID plus amoxicillin and clarithromycin, and PREVACID plus amoxicillin, no adverse reactions peculiar to these drug combinations were observed. Adverse reactions that have occurred have been limited to those that had been previously reported with PREVACID, amoxicillin, or clarithromycin.

**Triple Therapy: PREVACID/amoxicillin/clarithromycin**

The most frequently reported adverse events for patients who received triple therapy for 14 days were diarrhea (7%), headache (8%), and taste perversion (5%). There were no statistically significant differences in the frequency of reported adverse events between the 10- and 14-day triple therapy regimens. No treatment-emergent adverse events were observed at significantly higher rates with triple therapy than with any dual therapy regimen.

**Dual Therapy: PREVACID/amoxicillin**